KR20170082386A - Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof - Google Patents
Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof Download PDFInfo
- Publication number
- KR20170082386A KR20170082386A KR1020160001706A KR20160001706A KR20170082386A KR 20170082386 A KR20170082386 A KR 20170082386A KR 1020160001706 A KR1020160001706 A KR 1020160001706A KR 20160001706 A KR20160001706 A KR 20160001706A KR 20170082386 A KR20170082386 A KR 20170082386A
- Authority
- KR
- South Korea
- Prior art keywords
- stent
- group
- silicon
- silane compound
- layer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Abstract
A nanosilanated stent capable of selectively capturing endothelial progenitor cells, and a method for producing the same. According to this, the antibody can be efficiently fixed and the endothelial precursor cells can be selectively captured by the immobilized antibody to promote rapid re-endothelialization.
Description
To a nanosilanated stent capable of selectively capturing endothelial progenitor cells, and a method for producing the same.
Coronary artery disease is a disease that occurs in the blood vessels surrounding the heart, causing blood supply to the heart muscle. Treatment of coronary artery disease includes bygraft surgery, balloon angioplasty, and stenting to implant new blood vessels.
A stent is a cylindrical tube-shaped precision medical device that is used to normalize the blood flow by inserting the stent into a narrowed or blocked area when the blood vessel is clogged by blood clot or disease occurs and blood flow is obstructed. Stent implantation is much easier than surgery and has been used in recent years because of the lower incidence of restenosis compared to balloon angioplasty.
However, in about 20% of the patients after stenting, too much angiogenic tissue was formed between the stents, resulting in neointimal hyperplasia and restenosis which narrowed the vessel again. Drug-eluting stents, which release drugs that inhibit the overproduction of angiogenic tissues, have been used to significantly reduce the rate of stent restenosis. Drug-eluting stents solved the problem of restenosis but caused a new problem of stent thrombosis. After insertion of the bare metal stent, the endothelial cell completely covers the stent and the stent is not exposed to the blood vessel (re-endothelialization), but when the drug-releasing stent is inserted The endothelial cells do not cover the stent and the stent is exposed to the blood vessels and the platelets aggregate on the stent, resulting in stent thrombosis. In order to restore the vascular endothelium, there is a stent fixed on the surface of the stent with an antibody capable of capturing endothelial progenitor cells. However, the amount of immobilized antibody is small, the capture efficiency of the endothelial progenitor cells by the antibody is low, there is a problem.
Therefore, there is a need to develop a stent with an increased amount of immobilized antibody and an excellent capture efficiency of endothelial progenitor cells.
To provide a nanosilanated stent capable of selectively capturing endothelial progenitor cells.
To provide a method for producing a nanosilylated stent capable of selectively capturing endothelial progenitor cells.
One aspect provides a stent in which a silicon nanofilament layer, a silane compound layer, and a layer of material capable of specifically binding to a cell are sequentially bonded to the surface of a stent strut.
The silicone nanofilament may be a fiber including a silicon (Si) atom and having a nano-sized three-dimensional structure. The silicon nanofilament may be a polymer having a compound of the formula CH 3 -Si-O 3 as a unit.
The silane compound may include a silane compound including an amine group, a carboxyl group, an epoxy group, an aldehyde group, an acetyl group, a halogen group, a hydroxyl group, or a combination thereof.
The cell may be an endothelial progenitor cell, an endothelial progenitor cell, a late endothelial progenitor cell, an outgrowth endothelial cell (OEC), a circulating angiogenic cell (CAC), a colony forming unit- Hill: CFU-Hill), endothelial colony-forming cells (ECFC), or a combination thereof.
The substance capable of specifically binding to the cell may be an antibody or an antigen-binding fragment thereof, a vascular endothelial growth factor (VEGF), an aptamer, a peptide, or a combination thereof. The antibody or antigen-binding fragment thereof may be an antibody or an antigen-binding fragment thereof that specifically binds to CD146 protein, CD31 protein, vascular endothelial cadherin, CD133, or a combination thereof.
The stent may comprise a metal, a polymer, or a combination thereof. The metal may be selected from, for example, stainless steel, a nickel-chromium alloy, a nickel-titanium alloy, a cobalt-chromium alloy, a platinum-chromium alloy, tantalum, platinum, titanium, nitinol, aluminum, zirconium, chromium and nickel, Or a combination thereof. The polymer may be, for example, selected from the group consisting of polylactide, polyglycolide, polycaprolactone, polydioxanone, polylactic-glycolide, . An uncoated stent is also called a bare stent.
The bond may be a covalent bond, an ionic bond, a metal bond, a hydrogen bond, a van der Waals bond, or a combination thereof. The nanofilament layer, the silane compound layer, and a material layer capable of specifically binding to the cell can be sequentially coated on the surface of the stent framework by the binding. The stent can efficiently capture vascular progenitor cells and promote rapid re-endothelialization.
One aspect includes incubating a stent in the presence of a first silane compound to produce a stent with silicon nanofilaments bonded to the surface of the stent skeleton; Incubating the silicon nanofilament-bound stent in the presence of a plasma gas to introduce functional groups into the silicon nanofilament; Incubating the silicon nanofilament with the functional group introduced therein in the presence of the second silane compound to produce a stent in which the silicon nanofilament layer and the silane compound layer are sequentially bonded; And a silicon nano-filament layer, a silane compound layer, and a silane compound layer are sequentially incubated in the presence of a substance capable of specifically binding the cell to the silicon nanofilament layer, the silane compound layer, The method comprising the step of producing a stent in which a material layer is sequentially bonded.
The silicon nanofilaments, silane compounds, cells, substances capable of specifically binding to cells, stents, and bonds are as described above.
The method comprises incubating the stent in the presence of a first silane compound to produce a stent with silicon nanofilaments bonded to the surface of the stent framework.
The first silane compound may be a compound of formula (I)
R-Si-X n < / RTI >
In the above formula (I), R is selected from the group consisting of C 1 to C 18 , C 1 to C 16 , C 1 to C 14 , C 1 to C 12 , C 1 to C 10 , C 1 to C 8 , C 1 to C 6 , Or a C 1 to C 4 alkyl group. R can be methyl, ethyl, propyl, isopropyl, or butyl. In the formula (I), R is a C 2 to C 18, C 2 to C 16, C 2 to C 14, C 2 to C 12, C 2 to C 10, C 2 to C 8, C 2 to C 6 , Or a C 2 to C 4 alkenyl group. X may be a halogen element. For example, X is F, Cl, Br, I, At (astatine), or a combination thereof. And n may be an integer of 1, 2, or 3.
The compound of formula (I) may be selected from the group consisting of methyl trichlorosilane, vinyl trichlorosilane, trichlorosilane, trichlorododecyl silane, trichlorophenyl silane, trichlorophenethylsilane, trichlorodichloromethylsilane, triethyltrifluoro Methylsilane, trichlorohexylsilane, trimethyltrifluoromethylsilane, trichloro 2-chloromethylallyl silane,
The method includes incubating a silicon nanofilament-bound stent in the presence of a plasma gas to introduce functional groups into the silicon nanofilament.
The plasma gas may be oxygen plasma. The silicon nanofilament-bound stent is contacted with the stent in the presence of plasma gas for from about 1 minute to about 10 minutes, from about 1 minute to about 8 minutes, from about 1 minute to about 6 minutes, or from about 1 minute to about 4 minutes, Can be incubated. The functional group may be a hydroxy group. In one embodiment, a hydroxy group may be introduced to the silicon nanofilament by incubation in the presence of plasma gas.
The method comprises incubating a functionalized group-containing stent in a silicon nanofilament in the presence of a second silane compound to produce a stent in which the silicon nanofilament layer and the silane compound layer are sequentially combined.
The second silane compound may be a compound of formula (II)
AR m -Si-X n Formula (II).
In Formula (II), A may be an amine group, a carboxyl group, an epoxy group, an aldehyde group, an acetyl group, a halogen group, a hydroxy group, or a combination thereof. The R may be an alkyl group or a hydrophilic polymer. Wherein the hydrophilic polymer is selected from the group consisting of polyvinyl alcohol, polylysine, polyacrylic acid, polyacrylamide, polyurethane, poly (acrylonitrile-co-acrylic acid), polyethylene glycol, polyethyleneimine, chitosan, dextran, Lt; / RTI > M may be an integer of 1 to 30, 1 to 20, 1 to 10, or 1 to 5. X may be a halogen element. For example, X is F, Cl, Br, I, At, or a combination thereof. And n may be an integer of 1, 2, or 3. The compound of formula (II) may be aminopropyltriethoxysilane, carboxyethyltrichlorosilane, mercaptopropyltrimethoxysilane, or a combination thereof.
When the stent with the functional group introduced into the silicon nanofilament is incubated in the presence of the second silane compound, it can be incubated in nitrogen for the reaction in the gas or in an organic solvent for the liquid phase reaction. The incubation can be performed at a temperature of about 20 [deg.] C to about 37 [deg.] C. The incubation may be performed for about 1 hour to about 24 hours, for about 1 hour to about 18 hours, for about 1 hour to about 12 hours, or for about 1 hour to about 6 hours.
The method comprises incubating a silicon nanofilament layer and a silane compound layer sequentially in the presence of a substance capable of specifically binding the stent to the cell to specifically bind to the silicon nanofilament layer, the silane compound layer, and the cell And a layer of a material capable of forming a stent. The incubation may be performed at a temperature of about 4 째 C to about 37 째 C, about 10 째 C to about 37 째 C, or about 20 째 C to about 37 째 C. The incubation may be performed for about 1 hour to about 24 hours, for about 1 hour to about 18 hours, for about 1 hour to about 12 hours, for about 1 hour to about 6 hours, or for about 2 hours.
The method may further comprise binding at least one coupling substance to a stent in which the silicon nanofilament layer and the silane compound layer are sequentially bonded, a substance capable of specifically binding to cells, or a combination thereof. The coupling material may be ethylene dicarbodiimide, avidin, streptavidin, biotin, carboxypeptidase, sodium periodate, or a combination thereof. A substance capable of specifically binding to the stent and the cell can be bound by the coupling substance. In one embodiment, the stent and the antibody can bind by specifically binding streptavidin bound to the stent and biotin bound to the antibody.
According to one aspect of the nanosilanated stent and the method for manufacturing the same, the antibody can be efficiently fixed, and the endothelial precursor cells can be selectively captured by the immobilized antibody to promote rapid re-endothelialization.
FIG. 1 is a schematic view of a nanosilanated stent capable of selectively capturing endothelial progenitor cells according to one embodiment.
2 is a scanning electron micrograph showing the surface of a nanosilanated stent ('Stent-SiNf').
3 is a scanning electron microscope (SEM) image of the surface of a functionalized nanosilylated stent ('Stent-SiNf-APTES').
4A is a fluorescence micrograph to detect the antibody of a nanosilanated stent ('stent-SiNf-APTES-anti-CD146 antibody') with anti-CD146 antibody immobilized, (&Quot; stent-APTES-anti-CD146 antibody ").
Hereinafter, the present invention will be described in more detail with reference to Examples. However, these embodiments are intended to illustrate one or more embodiments, and the scope of the present invention is not limited to these embodiments.
Example 1. Endothelium Progenitor cell Specific antibody is immobilized Nano-silanization Stent Preparation and his effects
1. Silicon nanofilm layer coated Nano-silanization Stent Ready
(BMS, length x inner diameter = 18 mm x 1.8 mm, Bio Alpha) of a cobalt-chromium alloy material was prepared. The stent was exposed to oxygen plasma (CUTE, FEMTO science) for 5 minutes to generate a hydroxyl group on the surface of the stent. 200 ml of toluene (Sigma-Adrich) was added to the aluminum reaction vessel, and the vessel was filled with the stent exposed to the oxygen plasma. Thereafter, nitrogen containing 33 + 3% water was flowed into the reaction vessel to regulate the water content in the reaction vessel and toluene.
200 쨉 l of methyl trichlorosilane (Sigma-Adrich) was added to the reaction vessel and incubated at room temperature (about 25 캜) for 1 hour with stirring at a speed of 200 rpm. The stent was then removed from the reaction vessel and washed three times with toluene, ethanol, and a mixture of ethanol and distilled water (1: 1). The washed stent was incubated at a temperature of 120 DEG C for at least 1 hour to heat-treat the stent. The surface of the stent was confirmed using a scanning electron microscope (SEM) (Hitachi), and an SEM photograph was shown in Fig. 2 to confirm whether a nanosilane layer was formed on the surface of the stent.
In addition, for the gas phase silanation reaction, the stent was exposed to an oxygen plasma for 5 minutes to generate a hydroxy group. An aluminum reaction vessel was charged with an oxygen plasma exposed stent. Nitrogen containing 33 water was poured into the reaction vessel to regulate the water content in the reaction vessel. 200 쨉 l of methyltrichlorosilane (Sigma-Adrich) was added to the reaction vessel and incubated at room temperature (about 25 캜) for 1 hour. The stent was then removed from the reaction vessel and washed three times with toluene, ethanol, and a mixture of ethanol and distilled water (1: 1). The washed stent was incubated at a temperature of 120 DEG C for at least 1 hour to heat-treat the stent.
2. Nano-silanization Stent Function vaporization
To impart functional groups to the prepared nanosilylated stents, the nanosilylated stents were exposed to an oxygen plasma for 5 minutes to produce hydroxy groups. Hydroxy group-generated nanosilylated stents were immersed in a solution of 10 mM aminopropyltriethoxysilane (APTES) (Sigma-Adrich) in toluene (Sigma-Adrich) and incubated at room temperature for 2 hours. The nanosilylated stent was then removed from the reaction vessel and washed three times with toluene. The surface of the functionalized nanosilanated stent was confirmed using a scanning electron microscope (SEM) (Hitachi), and an SEM photograph is shown in FIG.
As a comparative group, a hydroxy group was generated by exposing the stent (BMS, length 18 mm and inner diameter 1.8 mm, Bio Alpha) of cobalt-chromium alloy material to oxygen plasma for 5 minutes. The stent was then added to a solution of 10 mM APTES (Sigma-Adrich) in toluene (Sigma-Adrich) and incubated at room temperature for 2 hours. Thereafter, the stent was washed three times with distilled water.
3. Fixation of antibody
An antibody to selectively capture endothelial progenitor cells was immobilized on the prepared nanosilanated stent as described in 2. above.
Specifically, anti-CD146 antibodies (R & D systems) were prepared to capture endothelial progenitor cells. Anti-CD146 antibody and a prepared nanosilylated stent were added to a mixture of 1-ethyl-3-dimethylaminopropylcarbodiimide and N-hydroxysuccinimide at a volume ratio of 1: 1, Lt; / RTI > Thereafter, the stent was washed three times using a phosphate buffer solution to prepare a stent having an antibody immobilized thereon.
4. Nano-silanization In the stent Identification of fixed levels of antibody
Anti-CD146 antibody-immobilized nanosilated stents prepared as described in 3. were mixed with mouse Alexa 488 conjugated anti-CD146 antibody (Santa Cruz biotechnology) and the mixture incubated at room temperature for 1 hour . The stent was then washed three times with phosphate buffered saline. As a comparative group, APTES coated stents (i.e., planar silanized stents) prepared as described in 2. were used.
The surface of the anti-CD146 antibody-immobilized nanosilylated stent and the silanized stent with anti-CD146 antibody immobilized (comparison group) were confirmed by fluorescence microscopy, and fluorescence photographs are shown in FIGS. 4A and 4B, respectively. As shown in Figs. 4A and 4B, it was confirmed that the amount of anti-CD146 antibody immobilized on the surface of the stent was increased in the nanostructured stent through nanosilanation compared to the planar silanized stent.
5. Nano-silanated Comparison of amount of immobilized antibody on metal surface
('Co-Cr-APTES') having a plane silane structure and a segment having a nanosilane structure ('Co-Cr-SiNf (1) -APTES '). Anti-CD146 antibody and Co-Cr-SiNf-APTES-anti-CD146 antibody were prepared by immobilizing the antibody on each metal surface as described in 3. above. Co-Cr-APTES and Co-Cr-SiNf-APTES without antibody immobilization were used as comparative groups.
The surface of the metal piece on which the antibody was immobilized was confirmed using a fluorescence microscope, and a fluorescence photograph was shown in Fig. 5A. Fluorescence intensity of the fluorescence was measured using a quantification program (Image J, National Institute of Health) and the results are shown in FIG. 5b.
As shown in FIGS. 5A and 5B, the Co-Cr-APTES metal fragments and the Co-Cr-SiNf-APTES metal fragments were similar in fluorescence intensity. The fluorescence intensity of the Co-Cr-APTES-anti-CD146 antibody fragment was about 20% higher than that of the Co-Cr-APTES and Co-Cr-SiNf-APTES metal fragments. In addition, the fluorescence intensity of the Co-Cr-SiNf-APTES-anti-CD146 antibody metal fragment was about 100%, which was about two times higher than that of the Co-Cr-APTES-anti-CD146 antibody fragment.
Therefore, it was confirmed that a large amount of antibody was strongly fixed on the nanosilanated metal surface.
Claims (16)
Incubating the silicon nanofilament-bound stent in the presence of a plasma gas to introduce functional groups into the silicon nanofilament;
Incubating the silicon nanofilament with the functional group introduced therein in the presence of the second silane compound to produce a stent in which the silicon nanofilament layer and the silane compound layer are sequentially bonded; And
The silicon nanofilament layer and the silane compound layer are sequentially incubated in the presence of a substance capable of specifically binding the stent to the cell to form a silicon nanofilament layer, a silane compound layer, and a substance capable of specifically binding to the cell Wherein the step of forming the stent comprises the step of forming a sequentially bonded stent.
R-Si-X n ????? (I)
Wherein R is a C 1 to C 18 alkyl group or a C 2 to C 18 alkenyl group, X is a halogen atom, and n is an integer of 1 to 3.
AR m -Si-X n ????? (II)
Wherein R is an alkyl group or a hydrophilic polymer, m is an integer of 1 to 30, and X is an alkyl group having 1 to 30 carbon atoms, X is an amino group, a carboxyl group, an epoxy group, an aldehyde group, an acetyl group, a halogen group, Lt; / RTI > is a halogen element and n is an integer from 1 to 3. < RTI ID = 0.0 >
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160001706A KR101772576B1 (en) | 2016-01-06 | 2016-01-06 | Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160001706A KR101772576B1 (en) | 2016-01-06 | 2016-01-06 | Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170082386A true KR20170082386A (en) | 2017-07-14 |
| KR101772576B1 KR101772576B1 (en) | 2017-08-30 |
Family
ID=59358778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160001706A KR101772576B1 (en) | 2016-01-06 | 2016-01-06 | Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101772576B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108588033A (en) * | 2018-04-24 | 2018-09-28 | 富恩生物技术（成都）有限公司 | Hybridoma cell strain, CD31 monoclonal antibodies, preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101251576B1 (en) | 2009-09-18 | 2013-04-08 | 서울대학교병원 | Antibody Coated Stent |
-
2016
- 2016-01-06 KR KR1020160001706A patent/KR101772576B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108588033A (en) * | 2018-04-24 | 2018-09-28 | 富恩生物技术（成都）有限公司 | Hybridoma cell strain, CD31 monoclonal antibodies, preparation method and application |
| CN108588033B (en) * | 2018-04-24 | 2021-09-24 | 富恩生物技术（成都）有限公司 | Hybridoma cell strain, CD31 monoclonal antibody, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101772576B1 (en) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Biomimetic Ti–6Al–4V alloy/gelatin methacrylate hybrid scaffold with enhanced osteogenic and angiogenic capabilities for large bone defect restoration | |
| Sargeant et al. | Covalent functionalization of NiTi surfaces with bioactive peptide amphiphile nanofibers | |
| Kim et al. | Synergetic cues of bioactive nanoparticles and nanofibrous structure in bone scaffolds to stimulate osteogenesis and angiogenesis | |
| Chen et al. | Surface biofunctionalization by covalent co-immobilization of oligopeptides | |
| Hu et al. | Regulation of the differentiation of mesenchymal stem cells in vitro and osteogenesis in vivo by microenvironmental modification of titanium alloy surfaces | |
| ES2330374T3 (en) | POLYMER COATING FOR MEDICAL DEVICES. | |
| CN103748147B (en) | The Medical Devices of plasma modification and method | |
| Kloss et al. | The role of oxygen termination of nanocrystalline diamond on immobilisation of BMP-2 and subsequent bone formation | |
| JP2020516386A (en) | Medical devices coated with polydopamine and antibodies | |
| KR101880576B1 (en) | Biocompatible implant | |
| MXPA04007898A (en) | Polymer coating for medical devices. | |
| Tan et al. | Surface modification of a polyhedral oligomeric silsesquioxane poly (carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells | |
| EP1207915A1 (en) | Novel multilayered material bearing a biologically active agent and the preparation thereof | |
| JP2005523050A (en) | Medical device having a coating that promotes endothelial cell adhesion and differentiation | |
| Xu et al. | Enhanced endothelialization on surface modified poly (L-lactic acid) substrates | |
| Lee et al. | Polydopamine-assisted BMP-2 immobilization on titanium surface enhances the osteogenic potential of periodontal ligament stem cells via integrin-mediated cell-matrix adhesion | |
| Lim et al. | Poly (lactic-co-glycolic acid) as a controlled release delivery device | |
| Vrana et al. | Double entrapment of growth factors by nanoparticles loaded into polyelectrolyte multilayer films | |
| Bachhuka et al. | Effect of surface chemical functionalities on collagen deposition by primary human dermal fibroblasts | |
| Liu et al. | Sustained release of magnesium ions mediated by a dynamic mechanical hydrogel to enhance BMSC proliferation and differentiation | |
| CN101357241A (en) | CD34 antibody or CD133 antibody surface orientation fixing method of titanium and titanium alloy cardiovascular implantation device | |
| Sutthavas et al. | The shape-effect of calcium phosphate nanoparticle based films on their osteogenic properties | |
| KR101772576B1 (en) | Nano-silanized stent for capturing selectively endothelial progenitor cell and preparation method therof | |
| Gan et al. | Artificial cilia for soft and stable surface covalent immobilization of bone morphogenetic protein-2 | |
| Böke et al. | Biological Activation of Bioinert Medical High-Performance Oxide Ceramics by Hydrolytically Stable Immobilization of c (RGDyK) and BMP-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |